Alexion Pharmaceuticals

• Discover Alexion
  • Facts & Figures
  • Photo Gallery
  • FAQ
• Meet Our Team
• Why Choose Alexion
• Locations
• Job Opportunities
• Compensation & Benefits
• Policies

Facts & Figures

• Over the past three years, we have doubled the number of our employees to more than 500.
• Since 2006 we have expanded from facilities in Cheshire, Connecticut and Paris to over 10 locations worldwide, including operations in Australia, Brazil, Canada, France, Germany, Italy, Japan, Switzerland and the United States.
• Soliris^® (eculizumab), our lead product, is now approved as a treatment for patients with PNH in 33 countries.
• Alexion invested over $800 million before its first therapy, Soliris, was approved by the FDA.
• Our positive cash flow from operations enables the company to make significant new investments in research and development programs.
• At least eight clinical trials are planned or underway to explore Soliris for the treatment of at least five other ultra-rare disorders. Alexion is also investigating its CD200 antibody for the potential treatment of patients with hematologic and solid-tumor cancers.
• Alexion was recently named one of the 500 fastest-growing companies in the United States and Canada by Deloitte.